Several lines of evidence have connected the benzodiazepine (BZ) receptor with either the mechanism of action of alcohol or as a potential monitor of the neurotoxic effects associated with alcoholism. Benzodiazepines show cross-tolerance and cross-dependence with alcohol. Inverse agonists at the BZ receptor reverse some alcohol-induced behaviors in rodents. Finally, postmortem studies of the brains of chronic alcoholic patients have shown reduced BZ receptor density and a loss of neurons. Despite these developments, clinical investigations of the function of the BZ have been difficult to design, primarily because of the inability to identify variables measurable in living human subjects which reflect central BZ receptor function. Functional imaging studies of the BZ receptor may be useful in both clinical and basic science studies related to alcoholism. Functional brain imaging with single photon emission computed tomography (SPECT) and positron emission tomography (PET) is a technique for noninvasively examining brain biochemistry in the living organism. The goal of this project is to assess the ability of tomographic imaging to measure quantitative changes in the benzodiazepine receptor population in vivo by SPECT imaging in nonhuman primates. We propose to use the benzodiazepine antagonist iomazenil (Ro 16-0154) radiolabeled with 123I for SPECT imaging. This compound binds reversibly with high affinity and specificity to the central type benzodiazepine receptor and the radiolabeled agent has excellent properties for in vivo imaging: high brain uptake and favorable absorbed radiation dose. The focus of this proposal is to rigorously test the following hypothesis: Can SPECT imaging quantitate benzodiazepine receptors? Preliminary results in our laboratories with SPECT and [123I]iomazenil have shown that relative measures, such as displacement by pharmacologically active agents, can be used to estimate in vivo ED50 of drugs acting on the benzodiazepine receptor.
The aim i s to extend the technique to estimate quantities such as receptor affinity (1/Kd), receptor number (B/max), and the binding potential (Bmax/Kd)by application of modeling under kinetic and equilibrium conditions.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Research Project (R01)
Project #
1R01AA009528-01A2
Application #
2045764
Study Section
Biochemistry, Physiology and Medicine Subcommittee (ALCB)
Project Start
1994-08-01
Project End
1996-07-31
Budget Start
1994-08-01
Budget End
1995-07-31
Support Year
1
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Yale University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520